gabexate has been researched along with umifenovir in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Cleland, E; Giovane, RA; Henderson, CE; Rezai, S | 1 |
1 review(s) available for gabexate and umifenovir
| Article | Year |
|---|---|
Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Disease Progression; Drug Combinations; Drug Repositioning; Esters; Gabexate; Gene Expression Regulation; Guanidines; Host-Pathogen Interactions; Humans; Hydroxychloroquine; Indoles; Lopinavir; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Spike Glycoprotein, Coronavirus | 2020 |
1 other study(ies) available for gabexate and umifenovir
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |